The cannabinoid CB 1receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA A receptors

British Journal of Pharmacology

Volumn 165, Issue 8, 2012, Pages 2479-2484

  Baur, R ^a   Gertsch, J ^a   Sigel, Erwin ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

AM251; CB 1 receptors; GABA; GABA A receptors; Positive allosteric modulation; Rimonabant (SR141716)

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; CANNABINOID 1 RECEPTOR ANTAGONIST; O 2050; RECOMBINANT 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1 BETA2; RECOMBINANT 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1 BETA2 GAMMA2; RECOMBINANT 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1 BETA3 GAMMA2; RECOMBINANT 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA4 BETA2 DELTA; RECOMBINANT 4 AMINOBUTYRIC ACID A RECEPTOR ALPHAX BETA2 GAMMA2; RECOMBINANT RECEPTOR; RIMONABANT; SI 141716; UNCLASSIFIED DRUG; (6AR,10AR) 3 (1 METHANSULFONYLAMINO 4 HEXYN 6 YL)6A,7,10,10A TETRAHYDRO 6,6,9 TRIMETHYL 6H DIBENZO(B,D)PYRAN; (6AR,10AR)-3-(1-METHANSULFONYLAMINO-4-HEXYN-6-YL)6A,7,10,10A-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO(B,D)PYRAN; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZOFURAN DERIVATIVE; CANNABINOID 1 RECEPTOR; DRUG DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAN DERIVATIVE; PYRAZOLE DERIVATIVE; RECOMBINANT PROTEIN; TETRAHYDROCANNABINOL;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ELECTROPHYSIOLOGY; FEMALE; IN VITRO STUDY; ION CURRENT; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOPUS; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

ANIMALS; BENZOFURANS; GAMMA-AMINOBUTYRIC ACID; OOCYTES; PIPERIDINES; PYRANS; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, GABA-A; RECOMBINANT PROTEINS; TETRAHYDROCANNABINOL; XENOPUS;

EID: 84856032927     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01405.x     Document Type: Article

References (34)

1. Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Barna I, Till I, Haller J (2009). Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: compound-specific and area-specific distribution within the brain. Eur Neuropsychopharmacol 19: 533-541.
3. A receptors. J Neurochem 103: 2556-2564.
4. A receptors expressed in Xenopus oocytes. Neuropharmacology 43: 695-700.
5. Di Marzo V (2008). CB(1) receptor antagonism: biological basis for metabolic effects. Drug Discov Today 13: 1026-1041.
6. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ et al. (1998). LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284: 291-297. (Pubitemid 28109558)
7. Fernandez JR, Allison DB (2004). Rimonabant Sanofi-Synthélabo. Curr Opin Investig Drugs 5: 430-435.
8. Fong TM, Shearman LP, Stribling DS, Shu J, Lao J, Huang CR-R et al. (2009). Pharmacological efficacy and safety profile of taranabant in preclinical species. Drug Dev Res 70: 349-362.
9. Gardner A, Mallet PE (2006). Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor silent antagonist. Eur J Pharmacol 530: 103.
10. Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A (1997). Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 61: 191-197.
11. Gibson HE, Edwards JG, Page RS, Van Hook MJ, Kauer JA (2008). TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 57: 746-759. (Pubitemid 351335342)
12. Hashimotodani Y, Ohno-Shosaku T, Kano M (2007). Endocannabinoids and synaptic function in the CNS. Neuroscientist 13: 127-137. (Pubitemid 46524316)
13. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S et al. (2007). Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316: 1494-1497. (Pubitemid 46906619)
14. Katona I, Freund TF (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14: 923-930.
15. Kim J, Alger BE (2010). Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. Nat Neurosci 13: 592-600.
16. Kunos G (2007). Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med 120: S18-S24.
17. Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Bátkai S (2008). Endocannabinoids and the control of energy homeostasis. J Biol Chem 283: 33021-33305.
18. Kunos G, Osei-Hyiaman D, Bátkai S, Sharkey KA, Makriyannis A (2009). Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 30: 1-7.
19. Leonti M, Casu L, Raduner S, Cottiglia F, Floris C, Altmann KH et al. (2010). Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin. Biochem Pharmacol 79: 1815-1826.
20. Lutz B (2009). Endocannabinoid signals in the control of emotion. Curr Opin Pharmacol 9: 46-52.
21. A receptor channels. Annu Rev Neurosci 17: 569-602.
22. Mendiguren A, Pineda J (2009). Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices. Br J Pharmacol 158: 1579-1587.
23. Menzies JR, Ludwig M, Leng G (2010). Direct and indirect effects of cannabinoids on in vitro GABA release in the rat arcuate nucleus. J Neuroendocrinol 22: 585-592.
24. Minier F, Sigel E (2004). Positioning of the alpha-subunit isoforms confers a functional signature to gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci USA 101: 7769-7774. (Pubitemid 38658104)
25. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62: 588-631.
26. Petrosino S, Di Marzo V (2010). FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 11: 51-62.
27. Piomelli D (2005). The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6: 672-679.
28. Rabow LE, Russek SJ, Farb DH (1995). From ion currents to genomic analysis: recent advances in GABAA receptor research. Synapse 21: 189-127.
29. Ross RA (2009). The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30: 156-163.
30. Seo K, Seino H, Yoshikawa H, Petrenko AB, Baba H, Fujiwara N et al. (2010). Genetic reduction of GABA receptor gamma2 subunit expression potentiates the immobilizing action of isoflurane. Neurosci Lett 472: 1-4.
31. Sieghart W, Sperk G (2002). Subunit composition, distribution and function of GABAA receptor subtypes. Curr Top Med Chem 2: 795-816.
32. Sigel E (1987). Properties of single sodium channels translated by Xenopus oocytes after injection with messenger ribonucleic acid. J Physiol 386: 73-90.
33. Sigel E, Minier F (2005). Educational paper: the Xenopus oocyte: system for the study of functional expression and modulation of proteins. Mol Nutr Food Res 49: 228-234. (Pubitemid 40445552)
34. Solinas M, Goldberg SR, Piomelli D (2008). The endocannabinoid system in brain reward processes. Br J Pharmacol 154: 369-383. (Pubitemid 351670594)